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Abstract: The use of TNF-alpha antagonists (infliximab, etanercept, adalimumab) has changed the course of many 
rheumatic diseases including rheumatoid arthritis (RA). Since their approval, some questions regarding their safety 
including infections have been observed. The aim of the study was to evaluate the changes in cytokines levels and cells 
subsets in patients with RA during anti TNF blocking agents treatment and the possible effect on infections’ development. 
We evaluated in 89 RA patients [39 treated with etanercept (ETN), 29 with adalimumab (ADA) and 21 with infliximab 
(IFN)] at baseline and after 6 months the following parameters: procalcitonin, ESR, CRP, cytokines as TNF, IL-6, IL-10, 
IL-8 and the TNF/IL-10 ratio, and peripheral mononuclear cells as CD3+, CD3+/CD4+, CD3+/CD8+, CD19+, CD3-
/CD16+/56+, CD14+HLADR+, CD20+, CD19+/CD38+. Peripheral mononuclear cells were detected by flow cytometric 
system Cytomics FC500 and cytokines circulating levels by a quantitative sandwich enzyme immunoassay technique 
(Human IL-8 Instant ELISAe Bioscience, Human IL-6 Instant ELISA e Bioscience, Human IL-10 Instant ELISAe 
Bioscience and Human TNF-a Quantikine immunoassay RD system). A lower reduction of CD14+HLADR+ in ADA 
group 54.6±10.4% vs ETA 48.4±15.7% vs INF 40.7±16.5%, p<0.039 was found. No differences in all three groups on 
peripheral mononuclear cells CD3+, CD3+/CD4+, CD3+/CD8+, CD19+, CD 20+, CD19+/CD38+, CD3-/CD16+/56+, 
and cytokine circulating levels were found. The number of infections at 6 months was: 10.3% in ADA group, 12.8% in 
ETN group and 19.04% in IFN group. A correlation was found between the reduction in CD14+HLADR+ cells and IFN 
treatment. Our data showed that the level of CD14+HLADR+ cells was reduced during therapy with IFN. ADA and ETN 
don’t reduce lymphocyte populations and their subsets such as CD14+HLADR+ cells that play an important role host 
defence. 
Keywords: Infections, TNF blocking agents, peripheral mononuclear cells. 
INTRODUCTION 
 Rheumatoid arthrtis (RA) has terrible effects on a wide 
range of health outcomes, ranges from bone damage to 
musculoskeletal system. RA is associated with increased 
mortality and comorbidity related to different causes 
compared to the general population, including infections [1, 
2]. Biologic therapies give the opportunity to target the 
precise immune and inflammatory pathway leads to improve 
the RA patients’ outcomes and to reduce the associated 
comorbidity and mortality. The anti-TNF drugs were the first 
biologic agents to become available in management of RA 
patients who fail to respond to traditional non-biologic 
Disease-modifying antirheumatic drugs (DMARDs). 
However, TNF plays an important role in host defence [3, 4]; 
consequently the introduction of anti-TNF agents induce the  
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necessity to evaluate and understand the effect of this drugs 
on infections’ risk. During bacterial infections as a sepsis 
different cytokines are secreted such as interleukin 1 (IL-
1), interleukin 6 (IL-6), and tumor necrosis factor  (TNF-
), and high levels of these cytokines can induce an 
increased risk of mortality [5], but anti-cytokines treatment 
cannot improve the patients survival [6]. Moreover, TNF 
release from macrophages play a crucial role in maintenance 
and formation of granuloma and in intracellular organisms 
the defence. Furthermore, TNF plays a role in leucocyte 
trafficking and Immune Complement (IC) clearance [7]. 
 The aim of the study was to evaluate the changes in 
cytokines levels and cells subsets in patients with RA during 
anti TNF- blocking agents treatment and the possible effect 
on infections’ development. 
MATERIAL AND METHODS 
 We evaluated 89 RA patients of a single centre that 
started a therapy with tumor necrosis factor  blocking 
agents in the period January 2008- December 2010, affected 
by RA according to the American College of Rheumatology 
34   The Open Rheumatology Journal, 2012, Volume 6 Benucci et al. 
(ACR) criteria 1998. We included 39 patients treated with 
etanercept (ETN), 29 with adalimumab (ADA) and 21 with 
infliximab (IFN) combined with corticosteroids (mean 
dosage 5,1±2.1 mg) and methotrexate (MTX) (mean dosage 
12.5 mg/weekly, range 20-7.5 mg). The patients were 
evaluated at baseline and after 6 months for the following 
parameters: procalcitonin, erythrocyte sedimentation rate 
(ESR), C-Reactive Protein (CRP), cytokine such as tumour 
necrosis factor-alpha (TNF-), IL6, IL-10, IL-8 and the 
TNF/IL-10 ratio, and peripheral mononuclear cells as CD3+, 
CD3+/CD4+, CD3+/CD8+, CD19+, CD3-/CD16+/56+, 
CD14+HLADR+, CD20+, CD19+/CD38+. 
 Peripheral mononuclear cells were detected by flow 
cytometric system Cytomics FC500( Beckman Coulter, 
Fullerton, CA, USA). We used the monoclonal antibodies 
CYTO-STAT tetra CHROME CD45FITC/CD4RD1, 
CD8ECD/CD3PC5, CD45FITC/CD56RD1/CD19ECD/CD3 
PC5, CD19PE/CD38PC5/CD20FITC, CD14FITC/HLADRP 
C5 and the absolute count and the percentage of 
lymphocytes were detected. Cytokine circulating levels were 
evaluated by a quantitative sandwich enzyme immunoassay 
technique ( Human IL-8 Instant ELISAe Bioscience, Human 
IL-6 Instant ELISAe Bioscience, Human IL-10 Instant 
ELISAe Bioscience and Human TNFa Quantikine 
Immunoassay RD System). 
 The study was approved by the Ethics Committees and 
written informed consent was obtained from patients before 
inclusion in the study. 
Statistical Analysis 
 Statistical analysis was performed using SPSS statistical 
package (SPSS Inc., Chicago, IL, USA; version 14.0, 2006). 
Quantitative variables were expressed as mean values and 
standard deviation. The associations between the quantitative 
variables were studied by means of correlation analysis, and 
those between the qualitative variables by means of 
contingency tables. Statistical significance was tested by 
ANOVA for parametric analysis and non parametric using 
the Kruskall-Wallis test. A two-tailed P value of <0.05 was 
considered statistically significant. 
 
RESULTS 
 The clinical characteristics of the patients included in the 
study are reported in Table 1. 
 No difference in baseline values among the  three treated 
group on mononuclear cells and cytokines was detected 
(Tables I and 2) We evaluated at baseline the normal range 
of peripheral mononuclear cells in donors health age 
matched. A lower reduction of CD14+HLADR+ in ADA 
group 54.6±10.4% vs ETA 48.4±15.7% vs INF 40.7±16.5%, 
p<0.039 was found after twenty-four weeks of treatment 
with anti-TNF agents. No differences in all three groups on 
peripheral mononuclear cells CD3+, CD3+/CD4+, 
CD3+/CD8+, CD19+, CD20+, CD19+/CD38+, CD3-
/CD16+/56+ and cytokine circulating levels was found after 
treatment with anti-TNFa agents (Tables 2 and 3). The 
number of infections at 6 months was: 10.3% in ADA group 
( 2 in respiratory tract, 1 in urinary tract), 12.8% in ETN 
group ( 3 in respiratory tract, 2 in urinary tract) and 19.04% ( 
3 in respiratory tract, 1 herpes zoster) in IFN group. No 
hospitalization was observed in the three groups. 
 No correlation between the number of infections in the 
group of INF and ETN and ADA was found. 
DISCUSSION 
 In this paper we have evaluated the role of the integrity 
of immune system and the variations under therapy with 
three different TNF blocking agents in RA patients during 
the first six months of treatment. RA patients have been 
recognised to be at increased risk of infection for several 
decades [8]. Given the involvement of CD14+ in disease, 
including sepsis and chronic heart failure, the discovery of 
signal transduction pathways activated exclusively via 
CD14+ is an important step towards the development of 
potential treatments involving interference with CD14+ 
functions [9]. 
 In human monocytes/macrophages pre-incubated with 
TNF-R1-expressing human endothelial cells, reverse 
signalling through transmembrane TNF-a mediated LPS 
resistance as indicated by the down-regulation of LPS-
induced soluble TNF-a and IL-6 as well as IL-1 and -10 [10]. 
Pre-treatment with soluble TNF-R1 for inducing reverse 
Table 1. The Clinical Characteristic of the Patients Included in the Study 
 
 Etanercept Group (39 pts) Adalimumab Group (29 pts) Infliximab Group (21 pts) 
Age mean years 59.6±9.8 58.7±10.6 60.1±9.3 
Disease mean 8.4±3.2 8.2±4.2 8.5±4.1 
Female/Male 33/6 25/4 19/2 
Corticosteroid dose mg 5.2±2.1 4.8±2.2 4.9±2.2 
Methotrexate dose mg/w 11.5±3.6 12.6±2.5 12.7±2.3 
RF positive 67% 68% 66% 
Anti CC-P positive  83% 81% 80% 
DAS28 4.8±1.4 4.7±1.6 4.6±1.5 
ESR mm/h 49.3±12.5 51.2±9.6 51.6±9.9 
CRP mg/dl 3.2±1.4 3.3±1.6 3.1±1.8 
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signalling through transmembrane TNF-a sensitized human 
monocyte cell line U937 cells to soluble TNF-a-induced 
activation, whereas stimulation of transmembrane TNF-a 
after soluble TNF-a-induced activation of U937 cells 
reduced mRNA stability of IL-1b and IL-8 [11]. In contrast 
to these findings that transmembrane TNF-a may inhibit 
sustained activation of monocytes, transmembrane TNF-a 
played a positive role in the activation of monocytes. 
Ligation of transmembrane TNF-a on monocytes by TNF-R2 
on T cells or soluble TNF-R2: Ig receptor construct 
(etanercept) induced TNF-a production due to outside-to-
inside signalling through transmembrane TNF-a [12]. 
 The effects of three TNF blocking agents are different 
on immune sistem [13]. Infliximab binds to both monomer 
and trimer forms of soluble TNF-a, whereas etanercept binds 
only to the trimer form [14]. Infliximab formed stable 
complexes with soluble TNF-a, while etanercept formed 
relatively unstable complexes. Each infliximab molecule is 
capable of binding to two TNF-a molecules, and up to three 
infliximab molecules can bind to each TNF-a homotrimer. In 
contrast, etanercept is supposed to form 1 : 1 complex with 
the TNF-a trimer [15]. 
 All the reports were in agreement that infliximab and 
adalimumab induced CDC (cytotoxicity dependent 
complement) much more potently than etanercept. In 
contrast, certolizumab pegol did not have any CDC activity 
[15], which reflects its absence of the Fc portion of IgG1. It 
is thus difficult for etanercept to make a membrane attack 
complex of complement proteins (C5b-C9) for CDC at least 
in vitro. 
 When activated human peripheral blood mononuclear 
cells were studied as target cells, none of these three anti-
TNF agents induced CDC [16], Infliximab, adalimumab and 
etanercept showed similar antibody dependent cell-mediated 
cytotoxicity (ADCC) activitiy using mTNF-transfected 
Jurkat T cells as target [17], while infliximab and 
adalimumab showed much more potent ADCC than 
etanercept in NS0 cells [15]. The discrepancy in etanercept-
induced ADCC is not clear, but may be explained by the 
different experimental conditions, such as difference in the 
species of target cell, in the expression level of 
transmembrane TNF-a. Both mAbs and etanercept weakly 
bound to Fcg receptors in the absence of soluble TNF-a, but 
in the presence of soluble TNF-a, there was a marked 
increase in binding only by mAbs infliximab and 
adalimumab [18]. As for infliximab, induction of both CDC 
and ADCC has been reported by others [19]. 
 Outside-to-inside signalling (reverse signalling) is a 
novel function of anti-TNF agents for the inhibition of TNF-
a-producing cells, which is mediated by mechanisms 
independent of CDC and ADCC [17-20]. Infliximab and 
adalimumab, but not etanercept, induced apoptosis and cell 
cycle G0/G1 arrest upon binding to transmembrane TNF-a-
expressing Jurkat T cells. Cross-linking of etanercept bound 
to the cell-surface transmembrane TNF-a resulted in 
increased apoptosis [20], which indicates that multimer 
formation with mAbs and transmembrane TNF-a may be 
essential for the initiation of the subsequent intracellular 
signals. IL-10 production was induced by infliximab, but not 
by etanercept, in transmembrane TNF-alpha-expressing 
Table 2.  The Values of Cytokines at Baseline and After 6 Months of Anti-TNFa Treatment 
 
Cytokines Value  
ADA Group 
Week 0 
ETN Group 
Week 0 
IFN Group 
Week 0 
ADA Group 
Week 24 
ETN Group 
Week 24 
IFN Group 
Week 24 
P Value 
TNFa pg/ml 33.1±12.3 33.1±12.3 34.4±12.6 86.7±70.3 171.4±69.4 182.5±47.4  NS 
IL-6 pg/ml 6.7±3.5 7.6±2.9 7,1±3.1 8.8±2.7 4.7±3.5 6.4±4.3  NS 
IL-10 pg/ml 3.2±1.5 3.6±2.1 2.5±1.6 3.9±2.8 2.5±2.3 5.5±5.1  NS 
IL-8 pg/ml 4.8±2.1 3.7±2.1 4.1±1.9 3.03±2.1 5.8±4.1 4.7±2.9.  NS 
TNFa/IL10 ratio  78.9±11.7 54.1±12.7  54.2±13.9.  78.9±11.7  54.1±12.7  54.2±13.9  NS 
 
Table 3. The Values of Lymphocytes at Baseline and After 6 Months of Anti-TNFa Treatment 
 
Cells 
ADA Group  
Week 0 
ETN Group 
Week 0 
IFN Group 
Week 0 
Normal Value in 
Donors Age Matched 
P  
Value 
ADA Group 
Week 24 
ETN Group 
Week 24 
IFN Group 
Week 24 
P  
Value 
CD3+ 1734±657 1725±688 1724±637 1100-1700 NS 1838±632 1653±736 1645±624 NS 
CD3+/CD4+ 1734±657 1134±317 1158±366 650-1400 NS 1250±496 1065±562 1067±446 NS 
CD3+/CD8+ 470±210 445±218 480±205 320-900 NS 520±230 489±223 534±321 NS 
CD19+ 268±89 245±92 259±91 200-400 NS 273±143 261±202 255±174 NS 
CD20+ 198±156 191±146 188±126 150-400 NS 193±179 164±85 99±17 NS 
CD19+/CD38+ 234±143 223±133 214±163 150-400 NS 240±155 109±74 79±15 NS 
CD16+/56+  211±72 217±68 213±67 200-400 NS 219±87 211±54 210±45 NS 
CD14+HLADR+% 57±12 55±14 59±12 50-90 NS 54.6±10.4 48.4±15.7 40.7±16.5 <0.039 
CD14+HLADR+ 345±213. 335±223 349±209 300-400 NS 326±214 311±230. 246±78 <0.05 
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Jurkat T cells [20]. We did’t evaluate in our study a 
subgroup of patients with RA without therapy with anti- 
TNF, but previous study has shown that RA patients have a 
nearly 2 -fold increased risk for infection compared with the 
age and sex matched control subjects for accelerated 
immunosenescence particularly of T cells [21]. Our data 
showed that no differences in all three groups on peripheral 
mononuclear cells CD3+, CD3+/CD4+, CD3+/CD8+, 
CD19+, CD20+, CD19+/CD38+, CD3-/CD16+/56+ and 
cytokine circulating levels were found after treatment with 
anti-TNF agents but the levels of CD14+HLADR+ markers 
of monocytes were reduced during therapy with IFN in the 
first six months and this could be a parameter of possible 
correlation with more infection that we have in this subgroup 
of patients with RA. Our data reveal that Adalimumab and 
Etanercept don't reduce lymphocyte population and subsets 
such as CD14+HLADR+ cells that have an important role 
against infections. Expression of class II major histocompati-
bility complex (MHC) on monocytes is a prerequisite for 
effective antigen presentation and processing, an important 
component of the immune response to infection [22]. It has 
been reported that the level of monocyte class II expression 
may identify patients who go on to develop infective 
complications following trauma [23]. Membrane CD14 
(mCD14), a 55-kD glycoprotein on the cell membrane of 
monocytes and polymorphonuclear cells, plays a key role in 
transmitting LPS signals intracellularly and ultimately 
activating tumor necrosis factor (TNF)-a production [24]. A 
animal model study showed that a monocyte mCD14 and 
HLA-DR expression decreased might contribute to 
endotoxin tolerance and a rapid reduction on LPS respon-
siveness [25]. The high reduction in patients in treatment 
with INF could be explained by the major effects of this 
monoclonal antibody on ADC and CDC. Moreover, it has 
been suggested that monoclonal antibodies carry a higher 
risk than ETN because of their different effects on different 
cells including this subset of monocytes [26]. 
 A review of observational research designs has revealed 
a higher risk of infections in the first few months of anti-
TNF treatment [27], followed by a progressive reduction and 
our finding confirm this data suggesting that these cells can 
play a role. 
 In the literature the data on infections induced by anti-
TNF agents were extrapolated by the Registers that involve a 
large amount of the patients [28,29]. A recent paper on a 
large cohort of 16.506 patients treated with anti-TNF showed 
7,1% of serious infections most of which were pneumonia, 
skin and soft tissue infections [30]. 
 Moreover, this is a pilot study focused on researching of 
some biomarkers associated with the infection risk that can 
help in clinical practice to prevent this complications. 
 Further studies are required to confirm these data and to 
define precise biomarkers for assessing and managing 
infections in RA patients treated with anti-TNF agents 
involving a large cohort of patients. 
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